Russian Journal of Skin and Venereal DiseasesRussian Journal of Skin and Venereal Diseases1560-95882412-9097Eco-Vector3675210.17816/dv36752Research ArticleKaposi's sarcoma: Pathogenesis and basic therapyPotekaevN. S-PanshinG. A-TeplyukN. P-ArsentyevN. S-VertievaE. Yuivertieva@gmail.comMakhovG. I-SizovaE. S-PaukovV. S-KartashovaM. G-I.M.Setchenov First Moscow State Medical UniversityRussian Center of X-Ray DiagnosisM.F. Vladimirsky Moscow Regional Research and Clinical Institute1506201316391321072020Copyright © 2013, Eco-Vector2013Two female patients with Kaposi’s sarcoma (KS) are described. In one KS manifested by typical and bullous efflorescence. Bullous KS developed as a result of secondary immunosuppression, caused by a long course of systemic glucocorticoid hormone (metiprede) and immunosuppressant endoxane for systemic scleroderma.Kaposi’s sarcomapathogenesis of KSbiological drugsсаркома Капошипатогенетические основы саркомы Капошибиологические препараты[Молочков В.А., Молочков А.В. Клиническая дерматоонкология. М.: МДВ; 2011.][Di Lorenzo G. Update on classic Kaposi sarcoma therapy: new look at an old disease. Crit. Rev. Oncol. Hematol. 2008; 68(3): 242-9.][Dal Maso L., Polesel J., Ascoli V., Zambon P., Burdoni M., Feretti S., et al. Classic Kaposi’s sarcoma in Italy. Br. J. Cancer. 2005; 92(1): 188-93.][Chang Y., Cesarman E., Pessin M., Lee F., Culpepper J., Knowles D.M., et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994; 266 (5192): 1865-9.][Rezaee Rahim S.A., Cunningham C., Davison A.J., Blackbourn D.J. Kaposi’s sarcoma-associated herpesvirus immune modulation: an overview. J. General Virol. 2006; 87(7): 1781-804.][Sullivan R., Dezube B.J., Koon H.B. Signal transduction targets in Kaposi’s sarcoma. Curr. Opin. Oncol. 2006; 18(5): 456-62.][Sullivan R.J., Pantanowitz L., Casper C., Stebbing J., Dezube B.J. Epidemiology, pathophysiology and treatment of Kaposi’s sarcoma-associated herpesvirus disease: Kaposi Sarcoma, primary effusion lymphoma and Multicentric Castleman disease. Clin. Infect. Dis. 2008; 47(9): 1209-15.][Knowles D.M., Cesarman E. The Kaposi’s sarcoma-associated herpesvirus (human herpesvirus-8) in Kaposi’s sarcoma, malignant lymphoma, and other diseases. Ann. Oncol. 1997; 8(2): 123-9.][Jin Y.T., Tsai S.T., Yan J.J. Detection of Kaposi’s sarcoma-associated herpesvirus-like DNA sequence in vascular lesions: a reliable diagnostic marker for Kaposi’s sarcoma. J. Clin. Pathol. 1996; 105(3): 360-3.][Alkharsah K.R., Dedicoat M., Blasczyk R., Newton R., Schulz T.F. Influence of HLA alleles on shedding of Kaposi sarcoma-associated herpesvirus in saliva in an African population. J. Infect. Dis. 2007; 195(6): 809-16.][Guerini F. R., Agliardi C., Mansuco R., Brambilla L., Biffi R.,Ferrucci S.,Zanetta L. Association of HLA-DRB1 and HLA-DQB1 with Classic Kaposi’s Sarcoma in Mainland Italy. Cancer Genom. Proteomics. 2006; 3: 191-6.][Guerini R., Mancuso R., Agostini S., Agliardi C., Zanzottera M., Hernis A., et al. Activating KIR/HLA complexes in classic Kaposi’s Sarcoma. Infectious Agents and Cancer. 2012; 7 (1):7-9.][Потекаев Н.С. Дерматовенерология - синтез науки и практики. Избранные труды. М.: Медицинская книга, 2004: 341-2.][Скрипкин Ю.К. Кожные и венерические болезни: Руководство для врачей. Скрипкин Ю.К., ред. М.: Медицина 1999; т.2: 554-68.][Каламкарян А.А., Мордовцев В.Н., Трофимова Л.Я. Клиническая дерматология: Редкие и атипичные дерматозы. Ереван; 1989: 465-6.][Volkow P., Zinser J.W., Correa-Rotter R. Molecularly targeted therapy for Kaposi’s sarcoma in a kidney transplant patient: case report, "what worked and what did not". BMC Nephrol. 2007; 27(8): 6.][Stallone G., Schena A., Infante B., Di Paolo S., Loverre A. Sirolimus for Kaposi’s Sarcoma in Renal-Transplant Recipients. N. Engl. J. Med. 2005; 352 (13): 1317-23.]